Table 4.

Ingenuity pathway analysis of pathways induced in reactive astrocytes

Ingenuity canonical pathwaysp valueGenes
Pathways induced in astrocytes after MCAO
    Acute phase response signaling1.66E-08SERPING1, SAA1, SERPINF2, IL6R, C4B, STAT3, HMOX1, OSMR, C1R, NRAS, NFKBIE, KRAS, SERPINE1, IL6, MYD88, TNFRSF1A, A2M, IL1RAP, IL1R1, SERPINA3, CEBPB, C1S, SOCS5, RRAS2, SOCS3, CP, C3, HPX
    IL-6 signaling1.45E-05TNFRSF1A, A2M, IL1RAP, IL6R, IL1R1, STAT3, CEBPB, TNFAIP6, HSPB1, CD14, RRAS2, NRAS, NFKBIE, MAP4K4, KRAS, IL6
    Hepatic fibrosis/hepatic stellate cell activation4.27E-05FAS, TNFRSF1A, A2M, ICAM1, IL1RAP, IL6R, IL1R1, CTGF, TLR4, CD14, TIMP1, MYL9, CXCL3, MYH9, CSF1, IGFBP4, IL6, IGFBP3, MET
    Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis1.26E-04PLCE1, PLCD3, CEBPA, IL6R, CAMK2D, STAT3, C1R, MYC, NRAS, CSF1, NFKBIE, CEBPD, KRAS, IL6, TLR2, ROCK2, MYD88, TNFRSF1A, ICAM1, ATF4, IL1RAP, IL1R1, TLR4, CCND1, CEBPB, C1S, FZD3, RRAS2, ADAMTS4, SOCS3, NFATC2, CEBPG
    Coagulation system2.40E-04BDKRB2, SERPINF2, A2M, PLAT, PROS1, PLAUR, SERPINE1, THBD
    PI3K/AKT signaling2.51E-04PTGS2, GDF15, PPP2R2A, YWHAG, MCL1, CCND1, HSP90AA1, CDKN1A, RRAS2, EIF4EBP1, GAB2, NRAS, HLA-B, NFKBIE, KRAS, MAP3K8
    RAN signaling4.57E-04IPO5, RANBP1, XPO1, RAN, KPNB1
    Germ cell–Sertoli cell junction signaling4.79E-04ACTN1, RND3, SORBS1, TNFRSF1A, A2M, TUBA1A, IQGAP1, TUBB, TUBA1C, MAP3K6, RRAS2, NRAS, TUBB6, RHOJ, TUBA3E, KRAS, MAP3K8, ZYX
    ERK5 signaling9.33E-04FOSL1, RRAS2, MYC, ATF4, YWHAG, NRAS, LIF, KRAS, MAP3K8, RPS6KA3
    HGF signaling1.23E-03PTGS2, CCND1, STAT3, CDKN1A, ELK3, ETS2, MAP3K6, RRAS2, NRAS, KRAS, IL6, MAP3K8, MET
    Aminosugars metabolism1.38E-03PDE1B, PDE12, NPL, CYB5R3, PDE4B, HK1, PDE3B, GFPT2, CYB5R1, HK2, HKDC1
    14-3-3-mediated signaling1.48E-03PLCE1, TNFRSF1A, YWHAG, PLCD3, TUBA1A, TUBB, TUBA1C, RRAS2, NRAS, TUBB6, TUBA3E, GFAP, VIM, KRAS
    IL-10 signaling1.74E-03CD14, FCGR2B, SOCS3, IL1RAP, IL1R1, STAT3, MAP4K4, NFKBIE, HMOX1, IL6
    p53 signaling2.14E-03CCNG1, FAS, GADD45G, DRAM1, GNL3, GADD45A, RPRM, THBS1, CCND1, CDKN1A, GADD45B, PERP
    PI3K signaling in B-lymphocytes2.34E-03PLCE1, PLCD3, ATF4, IRS2, TLR4, CAMK2D, FCGR2B, RRAS2, C3, NFATC2, NRAS, NFKBIE, ATF5, KRAS, ATF3
    Dendritic cell maturation3.39E-03TLR2, MYD88, TNFRSF1A, HLAC, ICAM1, ATF4, TLR4, COL18A1, FCGR2B, COL5A3, RELB, FSCN1, HLA-B, NFKBIE, IL6
    Thyroid cancer signaling3.72E-03BDNF, RRAS2, CXCL10, MYC, NRAS, CCND1, KRAS
    Type I diabetes mellitus signaling5.13E-03SOCS5, FAS, MYD88, TNFRSF1A, SOCS3, HLAC, CASP8, PTPRN, IL1RAP, IL1R1, HLA-B, NFKBIE
    ILK signaling5.37E-03ACTN1, RND3, PTGS2, TNFRSF1A, PPP2R2A, ATF4, PARVA, IRS2, CCND1, MYL9, MYC, FLNA, MYH9, RHOJ, VIM, FLNC
    Oncostatin M signaling5.75E-03CHI3L1, OSMR, RRAS2, NRAS, STAT3, KRAS
Pathways induced in astrocytes after LPS treatment
    Acute phase response signaling3.89E-08PIK3R1, SERPING1, SAA1, MYD88, A2M, RRAS, IL1R1, SERPINA3, C4B, C1S, OSMR, C1R, FN1, CP, C3, NFKBIE, LBP
    Antigen presentation pathway3.98E-08B2M, HLA-C, HLA-E, PSMB9, HLA-B, PSMB8, TAP2, TAPBP
    Interferon signaling1.74E-06IFITM1, IRF9, OAS1, IFI35, PSMB8, IFIT3, IFNAR2
    Hepatic fibrosis/hepatic stellate cell activation2.88E-06ICAM1, A2M, SMAD3, IL1R1, IFNAR2, TIMP1, CD14, TGFBR2, FN1, CXCL3, LBP, PGF, MET
    Virus entry via endocytic pathways5.89E-05PRKCA, PIK3R1, B2M, HLAC, PRKCD, RRAS, FLNA, HLA-B, CAV1
    Glioma invasiveness signaling1.12E-04TIMP1, F2R, PIK3R1, RHOU, RRAS, RHOJ, CD44
    Role of pattern recognition receptors in recognition of bacteria and viruses1.20E-04IFIH1, PIK3R1, TLR2, MYD88, OAS1, C3, DDX58, PTX3
    Protein ubiquitination pathway1.26E-04USP18, UBE2V2, PSME1, B2M, HLA-C, PSMB9, HSPB8, PSMB10, TAP2, HSPB1, BIRC3, HLA-B, PSMB8, PSMB2, HSPB6
    Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis2.09E-04PIK3R1, TLR2, MYD88, ICAM1, PRKCD, RRAS, IL1R1, CAMK2D, CCND1, C1S, PRKCA, C1R, FN1, IL17RA, NFKBIE, CEBPD, PGF
    Complement system2.19E-04C1S, SERPING1, C1R, C3, C4B
    OX40 signaling pathway4.90E-04B2M, HLA-C, HLA-E, HLA-B, NFKBIE
    Caveolar-mediated endocytosis signaling5.13E-04PRKCA, FLOT1, B2M, HLA-C, FLNA, HLA-B, CAV1
    LPS-stimulated MAPK signaling5.62E-04CD14, PRKCA, PIK3R1, PRKCD, RRAS, NFKBIE, LBP
    HGF signaling7.76E-04PRKCA, PIK3R1, MAP3K6, PRKCD, RRAS, CCND1, CDKN1A, MET
    Germ cell–Sertoli cell junction signaling8.13E-04PVRL2, PIK3R1, SORBS1, MAP3K6, TGFBR2, RHOU, A2M, RRAS, RHOJ, GSN
    HER-2 signaling in breast cancer9.12E-04NRG1, PRKCA, PIK3R1, PRKCD, RRAS, CCND1, CDKN1A
    fMLP signaling in neutrophils1.23E-03PRKCA, PIK3R1, PRKCD, RRAS, ARPC5, NFKBIE, ARPC1B, ITPR1
    Allograft rejection signaling1.35E-03B2M, HLA-C, HLA-E, HLA-B
    Thrombin signaling1.35E-03F2R, ADCY9, PRKCA, PIK3R1, RHOU, PRKCD, RRAS, CAMK2D, MYLK, RHOJ, ITPR1
    Dendritic cell maturation1.58E-03PIK3R1, TLR2, RELB, MYD88, B2M, HLA-C, ICAM1, HLA-B, NFKBIE
  • Shown are the top 20 canonical pathways identified using Ingenuity Pathway Analysis of genes more than twofold significantly enriched in MCAO and LPS reactive astrocytes. Bold is used for emphasis.